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1. Introduction 
Therapeutic hypothermia has been around for centuries, ancient Egyptians, Greeks, and 
Romans have used it. 
Hypothermia is any body temperature below 36 degree C. 
Therapeutic Hypothermia is induced hypothermia and can be mild (34-35.9 degree C), 
moderate (32-33.9 degree C), moderately deep (30.1-31.9 degree C) or deep (less than 
30degree C). 
 
 
 
Figure 1. Current indications for induced therapeutic hypothermia 
Cardiopulmonary resuscitation Class-I
Traumatic brain injury (ICP CONTROL) Class I
Traumatic brain injury ( outcome) Class IIa
Stroke Class-III
Fever in patients with neurological injury Class IIb
Subarachnoid hemorrhage- vasospasm 
prevention 
Class-IV
Intraoperative hypothermia for intracerebral 
aneurysm surgery  
 
Class-IIb
Intraoperative hypothermia for thoraco-
abdominal aortic aneurysm
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2. Cardiac arrest 
Despite advances in ICU care, cardiac arrest remains a significant cause of death in many 
countries. Mortality reports vary from 65 to 95% for out-of hospital cardiac arrest. I is a class 
–I recommendation now that  after return of spontaneous circulation in  out-of-hospital VF 
cardiac arrest , patients that remain comatose should be subjected to hypothermia at 32°C to 
34°C for 12 to 24 hours. This may also be applied to comatose adult patients with 
spontaneous circulation after OHCA from a non VF rhythm or in-hospital cardiac arrest.1 
Several unanswered questions however remain, due to lack of randomized studies. These in 
part, relate to time from initiation of therapy to achieving target temperature, and whether 
this is a significant predictor of outcome. The optimal rate of cooling is also an unanswered 
question, so is the optimal duration of TH in some settings, albeit in the setting of cardiac 
arrest, improved outcomes have been demonstrated with 12 and 24 hrs of TH at 32°C to 
34°C. Hypothermia for neonatal asphyxia is commonly performed for 72 hrs, while 
hypothermia for cerebral edema associated with liver failure has been reported for as long 
as 5 days. 2 
3. TBI 
Traumatic brain injury (TBI) is a leading cause of death and disability in young people in 
Western countries. The neuroprotectant effects are thought to be related to decreased 
metabolic rate, cerebral blood flow, decreased release of excitatory neurotransmitters, 
decreased apoptosis, cerebral edema, decreased cytokine response etc.3 
While studies have shown that Hypothermia is clearly effective in controlling intracranial 
hypertension (level of evidence: class I); it has been difficult to show that lowering ICP 
definitely improves outcomes. Few positive studies with regard to survival and improved 
neurological outcome have been shown mainly in tertiary referral centers with experience in 
use of hypothermia. Here again, as in cardiac arrest, more unanswered questions remain- 
duration, time of cooling and rewarming, type of rewarming. Currently, most centers 
perform it for at least 48 hours. Rewarming is typically done slowly, over at least 24 h (level 
of evidence: class IIa). 4 If there is evidence of ICP elevation during rewarming, again no 
definite recommendations are available, but most experts will proceed with repeat cooling.  
It could be that in traumatic brain injury, other therapies, including cerebrospinal fluid 
drainage, osmolar therapies, sedation, barbiturate coma, and decompressive craniectomy 
may confer additional benefits that may make it more difficult to prove that Therapeutic 
hypothermia is superior.  
4. Stroke 
Similar to Cardiac arrest and TBI there is evidence from animal studies that show benefits of 
therapeutic hypothermia in stroke. Use of hypothermia in stroke remains experimental, 
until large prospective randomized human clinical trials using hypothermia in acute stroke 
are completed. 5 
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5. MI 
Hypothermia may decrease infarct size in patients with acute myocardial infarction after 
emergency percutaneous coronary intervention 
6. Other indications 
Intraoperative hypothermia is used during neurological surgery but without strong 
evidence from randomized controlled trials. Indications are being studied in the areas of 
SAH, Neurosurgery, liver failure, Spinal cord injury. 
7. Induction of hypothermia 
Methods 6 
Both Invasive and non invasive cooling methods have been developed and used to induce 
hypothermia. The ideal cooling technique should offer efficacy, speed of cooling for target 
organs, and offer ease of use and transport. It should also have the ability to provide 
controlled rewarming. 
Surface cooling: Dine et al 
Surface cooling as a noninvasive method to induce hypothermia is easy to use, on the other 
hand requires more time to achieve the target temperature. There are two described 
methods: generalized cooling, and selective brain cooling. 
Generalized cooling is achieved through the use of cooling blankets, ice packs, and cooling 
pads. Care should be paid to prevent cold injury to the patient’s skin. This method has 
variability in time to cooling, ranging from 0.03 to 0.98 °C per hour and difficulty in titration 
of temperature.  
Pads that provide direct thermal conduction through the skin are also used; these are unlike 
conventional water blankets or wraps where heat transfer is by convection. The cooling rate 
is reported to be 1.5°C/hour or more. Hydrogel-coated pads in these circulate temperature-
controlled water under negative pressure, and are placed usually on the patient’s abdomen, 
back and thighs. 
Selective brain cooling is another non invasive method. The most commonly used methods 
are cooling caps and helmets that contain a solution of aqueous glycerol to facilitate heat 
exchange. Helmet devices do not appear to provide particularly significant protection to the 
brain, but they reduce core temperature slowly. 
Several other limitations exist in surface cooling methods. Through vasoconstriction, 
shivering, redirection of blood flow away from extremities, they create thermal energy.  
Overcooling occurs. In a study involving 32 patients where surface cooling was used to 
induce hypothermia, 63% of patients were overcooled, increasing the risk for adverse 
events. Another problem with surface cooling is cold injury, causing pressure ulcers and 
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skin breakdown. Surface cooling is less efficient in reducing the temperature of target 
organs, such as the brain and heart6 
Invasive cooling 
30 ml/kg Lactated Ringers solution that has been chilled to 4°C can be infused over 30 
minutes. No adverse effects of the rapid infusion of this volume of IV crystalloid fluid in a 
study by Bernard. This is followed by another method to maintain hypothermia. Different 
types of fluids can be used, including 0.9% sodium chloride injection, lactated Ringer's 
injection, and albumin. Studies have reported cooling rates of 0.8–1.2 °C per liter of fluid 
infused. Some experts caution that in patients unable to handle the fluid challenge, infusion 
of large volumes of intravenous fluids in the presence of pulmonary edema or chronic renal 
failure requiring dialysis may increase adverse events. However , several studies have 
shown that this process has not been associated with worsening pulmonary edema.7 
Endovascular cooling is another invasive method used. This is achieved by inserting central 
venous catheters, with an external heat exchange-control device that circulates cold 
intravenous fluid. The user sets a target temperature, and the device appropriately adjusts 
the fluid /water temperature. These devices can reduce temperatures at rates close to 4 °C 
per hour. In a study by Holzer and colleagues, looking at post cardiac arrest patients, 
endovascular cooling was found to improve survival and short-term neurologic recovery 
without higher rates of adverse events, compared with standard treatment. Furthermore, 
the constant rate of rewarming prevents elevations in ICP. As with any central venous 
catheters, insertion risks and infectious, bleeding complications may occur. The placement 
of catheters with associated risks and, and costs of placing them need to be factored. 8 
Other methods for invasive cooling that are reported include cold carotid infusions, single 
carotid artery perfusion with extracorporeal cooled blood, ice water nasal lavage, cold 
peritoneal and lung lavage and nasogastric and rectal lavage 
Monitoring temperature 
Temperature must be monitored continuously and accurately during TH. Peripheral and 
core temperatures may not always correlate, so two methods of monitoring are usually 
recommended. A true core temperature is obtained from a pulmonary artery catheter. 
Tympanic temperatures poorly reflect core temperature. Bladder temperatures are easily 
obtained by temperature-sensing indwelling urinary catheters. Studies have shown that 
bladder temperatures are continuous, safe and reliable, correlate well with fluctuations in 
core temperature. Clinicians must be mindful that in oliguric patients, bladder temperature 
may poorly reflect core temperature, and other monitoring sites should be used. There is 
also a delay in reflecting core temperature changes, before bladder temperature also 
changes, especially the more rapid the cooling rate. This is more of a problem with rectal 
temperatures. Education of the caregivers about this helps prevent undercooling or 
overcooling the patient, thereby helps to mitigate the risk of adverse events. Stone, Gilbert J et al 
 
Therapeutic Hypothermia: Adverse Events, Recognition, Prevention and Treatment Strategies 7 
8. Phases of temperature modulation in therapeutic hypothermia2 
Temperature modulation during therapeutic hypothermia may be broken down into four 
phases: induction, maintenance, rewarming/ decooling, and normothermia. Each of these 
phases requires monitoring for and prevention of associated complications.(please refer to 
Figure 2 for an example of a therapeutic hypothermia protocol used in our institution for 
cardiac arrest patients). 
DO NOT SUBSTITUTE              STAT MEDICATION ORDER 
 PLEASE INCLUDE: PHYSICIAN NAME, NUMBER AND SIGNATURE 
 DATE TIME Hypothermia Induction Order Set                                                                            Page 1 of 2 
   Indication:                                                                                                            Patient weight:               kg 
    NS - 30 mL/kg IV of cold injection at a target of 4° Celsius STAT 
   
Initiate cooling with the appropriate hypothermia induction device according to Hypothermia 
Induction policy 
    Apply pads appropriate for patient weight(Apply Universal pads if Wt>= 220 LBs) 
    The Arctic Sun is preset to 33° Celsius 
    Start Magnesium Sulphate 4 Gm IV (in 100 ml injectable water ) over 4 hours 
   Nursing
    Continuous cardiac monitoring with pulse oximetry - monitor vital signs and record every hour 
   
 Consider target MAP ≥ 90mmHg or          mmHg to maintain Cerebral Perfusion Pressure (CPP) of 
____ 
   
 Goal CVP 8-12mmHg or               mmHg 
 Maintain ScvO2 > 70%.(if available) 
   
 Obtain bedside glucose every  1   hour. (See Adult Insulin order sheet if already initiated.)Maintain 
Accuchecks q 1 Hr until T=37° Celsius.(maintain BS=110-150) 
    ABG every           hour(s) 
    CBC, BMP, Magnesium, Phosphorus, PT/PTT every 6 hours 
    Consider blood cultures 12 hours after initiation of cooling 
    Initiate VAP Bundle Order Set, if not already begun 
    No sedation vacation if patient is receiving neuromuscular blockade infusion or in cooling phase  
   
 Consider Empiric Antimicrobial therapy if sepsis or immunosuppression is suspected(ex: 
neutropenia..) 
   Activity
    Bedrest 
    Skin assessment should be performed and documented every 4 hours 
    Turn patient every two hours unless contraindicated and ordered 
    PT/OT consults and treatment if not already ordered 
   Sedation/Analgesia/Control of Shivering
   
 Propofol (DIPRIVAN) drip initiated at 10mcg/kg/min. - titrate by 5mcg/kg/min for Ramsay of _____ 
to a max. of 80mcg/kg/min 
    Midazolam (VERSED) drip initiated at           mg/hour - titrate by 1mg/hr for Ramsay of _____ 
    Fentanyl infusion at           mcg/hour - titrate to              mcg/hour 
    Morphine infusion at                 mg/hour - titrate to                 mg/hour 
   If still shivering (physical assessment or trend indicator) give:
   Buspar  10mg/ 20mg PT TID(circle dose) 
 DATE TIME Hypothermia Induction Order Set                                                                           Page 2 of 2 
   If still shivering, consider neuromuscular blockade:
   
 Start with PRN dosing as ordered for shivering 
 If patient still shivering, consider continuous infusion.   
 Place “Neuromuscular Blockade in use” sign at head of bed.          
   
 Atracurium  Intermittent dosing__________________________(dose/route/interval) 
 Loading dose  (0.5 mg/kg) = ________ mg IV x one dose now 
 Infusion – begin at 4 mcg/kg/min IV to a max. of 12 mcg/kg/min 
   
 Vecuronium  Intermittent dosing__________________________(dose/route/interval) 
 Loading dose (0.1 mg/kg) = ________ mg IV x one dose now 
 Infusion – begin at 1 mcg/kg/min IV to a max. of 2 mcg/kg/min 
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   Paralytic Titration
    Monitor patient for ventilator compliance and shivering 
   
Continuous EEG(please choose one of the following):
 
    Start now and D/C when patient is rewarmed to 37° Celsius - page EEG tech  
    Start in am and D/C when patient is rewarmed to 37° Celsius - page EEG tech 
   
Respiratory:
 Maintain O2 Sats=95% 
 Maintain pCO2=40mmHg 
   Medications
   
 Artificial tears ophthalmic ointment (LACRILUBE or equivalent) – one ribbon in each eye every 12 
hours. 
    Maintenance IV Fluids:                          at                ml/hr.-Titrate to maintain equal to UO. 
   Rewarming - To start 24 hours after temperature of 33° Celsius is attained
    Continuous EKG for dysrhythmias 
    Stop all potassium infusions 
   
 Rewarm at 0.25° Celsius to 0.33° Celsius per hour -  
 Keep patient in goal temperature range of 36° Celsius to 37° Celsius for next 48 hours 
    May discontinue paralytic(if used) once goal temperature is obtained 
    Begin daily sedation vacation once paralytic has been discontinued 
   Once rewarmed, please maintain EUTHERMIA(~37° Celsius). 
Figure 2. Mercy Hospital St Louis In-HOSPITAL Therapeutic Hypothermia Protocol 
In the setting of cardiac arrest, based on animal and human data, initiation of cooling should 
be done as soon as possible after return of spontaneous circulation (ROSC). The induction 
phase can be initiated in the prehospital or in hospital setting. There are ongoing studies 
involving prehospital cooling. One should be mindful that if prehospital cooling is not 
followed by in hospital cooing, outcomes could be considerably worse, especially if patients 
are rewarmed quickly  
The maintenance phase usually occurs in an intensive care unit and hemodynamic 
parameters, electrolytes should be watched closely. For example, hypokalemia is a common 
occurrence, and can precipitate further arrests, so replacement is essential. Secondary insults 
such as hypercarbia, hypoxemia, glycemic shifts should be avoided. It is important to 
recognize that drug metabolism is altered in hypothermia, meticulous attention to 
medication dosing is needed and aggressive treatment of shivering, with sedation and 
neuromuscular blockade is often needed 
Fever in the first 72 hrs after ROSC is associated with poor outcome. Although unproven, an 
increasing body of evidence supports the cautious prevention and treatment of fever in the 
setting of critical neurological illness, and many clinicians attempt to maintain a core 
temperature of 36°C to 37.5°C until at least 72 hrs after ROSC 
Rewarming /Decooling is associated with electrolyte shifts, vasodilation, and the “post 
resuscitation” syndrome, many deaths occur in this phase due to hemodynamic instability 
and other complications. Rewarming / Decooling should not be treated casually. 
The “post resuscitation” syndrome which is characterized by elevated inflammatory 
cytokine levels, vasodilatory shock, intracranial hypertension, and thereby decreased 
cerebral perfusion pressure often compounds the myocardial dysfunction related to acute 
myocardial infarction, defibrillation injury or cardiomyopathy. The duration of cooling and 
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rewarming may vary depending on the indication, for instance, in post cardiac arrest, 
rewarming is usually begun 24 hours after the initiation of cooling, in intracranial 
hypertension, this is typically done later, after 48 hours. Patients should be rewarmed 
slowly so that it avoids rapid hemodynamic alterations, while preserving the 
neuroprotectant effects of hypothermia. The usual rate of rewarming is a goal rate of 0.2°C 
to 0.33°C per hour, in ICP elevations; the rate is sometimes slower, at 0.05 to 0.1 degrees C 
per hour. While the optimal rewarming rate remains unknown; the process usually takes 
about 8 hours. Careful hemodynamic monitoring is needed, patients may require additional 
hemodynamic support with fluid boluses, inotropes, and vasopressors to maintain adequate 
cerebral perfusion pressures, and mean arterial pressures during decooling, Sometimes, if 
significant hemodynamic instability or signs of elevated ICP occur, it may become necessary 
to slow or stop the temperature decooling process. Rewarming is typically  achieved 
through active or passive means through the use of heated-air blankets, or the removal of 
cooling methods allowing the patient's body temperature to increase over time. Paralysis 
and sedation should be maintained until the patient's temperature reaches 35 °C. Patients 
must be monitored closely, and all electrolyte infusions must be discontinued to avoid 
dangerous electrolyte shifts 
Physiological effects of hypothermia 
Hypothermia affects many intracellular processes. While some of these are directly related 
to its protective effects, hypothermia therapy is also known to be associated with a number 
of potential adverse events. These adverse effects generally do not pose a problem until core 
body temperatures are< 35°C. 
Many physiological, laboratory changes occur with induction of hypothermia.  Education of 
caregivers is key, so there is not only timely recognition of adverse events, but unnecessary 
interventions are minimized in case of routine changes that are seen. It is possible that in 
many studies especially in traumatic brain injury and hypothermia, the results may have 
been negatively impacted by adverse events related to hypothermia and /or failure to 
recognize and treat the physiological effects. 
Example, mild hypothermia is associated leucopenia, thrombocytopenia. Hyperglycemia is 
common due to decreased insulin sensitivity and increased insulin resistance. Decreases in 
cardiac output may be seen, also an increase in lactate levels and levels of serum 
transaminases, amylase. A common occurrence is increased urinary output (cold diuresis). 
These effects of hypothermia depend on the degree of hypothermia, age, comorbidities. A 
significant risk for severe arrhythmias occurs at temperatures below 28–30°C. These low 
temperatures are not typically used in current practice; the target temperature is usually 
mild –moderate hypothermia, although they are still practiced in major vascular and other 
neurosurgical procedures.4 
Hypothermia leads to a decrease in the metabolic rate. Metabolism is reduced by between 
5% and 7% per Celsius degree reduction in body temperature. Cerebral blood flow is 
decreased, but, this is offset by the decrease in metabolism. It decreases cerebral edema, 
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decreases the excessive influx of Ca2+ into the cell, decreases the accumulation of glutamate, 
an excitatory neurotransmitter. It thereby is thought to decrease apoptosis. 
Hypothermia inhibits neutrophil and macrophage function, suppresses inflammatory 
reactions and inhibits the release of pro-inflammatory cytokines. While this may help 
contribute to hypothermia’s neuroprotective effects, this may occur at the expense of an 
increased the risk of infections.  
 
Figure 3. Adverse events of Hypothermia, prevention and management strategies: 
Shivering 
Shivering is the body’s physiological response to hypothermia. Both in the induction and 
maintenance of hypothermia, this can pose challenges, and shivering is sometimes more an 
issue when normothermia is the goal temperature. Shivering generates heat and increases 
the oxygen consumption and metabolic demands of tissues.  
Shivering is especially important in the extremes of age. It has been associated with a higher 
risk of adverse cardiac events and poor outcomes in the perioperative setting. The threshold 
for shivering is slightly higher in females. The process is regulated via the preoptic nucleus 
of the anterior hypothalamus. Through positive and negative feedback loops this helps 
minimize fluctuations, maintains core body temperature within 0.1°C– 0.2°C. 4 
Typically a shivering response is seen when core temperature decreases below 35.5°C, the 
“shivering threshold.” However, in febrile patients, and in brain injured patients, this 
regulation is altered and both the temperature “set point” and the shivering threshold 
increase. The hypothalamus then makes attempts to maintain the higher temperatures as it 
Shivering 
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does to maintain normal temperature or normothermia. This causes an increase in oxygen 
consumption, metabolic rate, and increases carbon dioxide production. At temperatures 
lower than 33-34°C, the shivering response decreases, therefore sedation and paralytics can 
be decreased at this point, if the clinical situation allows it. 
The Bedside Shivering Assessment Scale (BSAS) is a simple scale that was developed as a 
means to detect and quantify shivering and guide therapeutic interventions. The scale has 4 
levels. 9 
 
Score Description or observation Severity 
0 Absence of shivering on palpation of neck or pectoralis muscles None 
1 Localized to the neck and/or thorax Mild 
2  Involvement of the upper extremities with or without neck Moderate 
3 Generalized, whole-body involvement Severe 
Table 1. Bedside Shivering assessment Scale 
A non pharmacologic measure that has been shown to decrease shivering in some studies, 
mainly in healthy volunteers is called Surface counter warming. Studies have shown 
decreased shivering and improved metabolic profiles, and that is safe and effective, easy to 
use. Theoretically, an increase of 4°C in skin temperature could compensate for a 1°C 
decrease in core temperature, reducing the shivering response.9 
Numerous pharmacologic strategies have been used to control shivering. In the operating 
room, volatile anesthetics, including halothane, isoflurane and enflurane, are used to 
control post anesthetic shivering. In the intensive care unit, other agents are of more 
practical use. These agents are thought to be effective by various mechanisms. The agents 
act though serotonin manipulation, or are N-methyl-D-aspartate Antagonists, α2-agonists, 
Opioids, and others. Most studies involving these agents have been conducted in healthy 
volunteers. 
Buspirone is a serotonin (5-HT) 1A partial agonist that has been shown to be a good anti 
shivering agent. At a 60-mg dose, buspirone – a 5-HT1a partial agonist – reduced the 
shivering threshold by 0.7°C. A study in volunteers found that a 30-mg dose combined with 
low-dose meperidine produced a similar reduction in shivering threshold compared to a 
large dose of meperidine alone (2.3°C).Buspirone provides a good synergistic therapy when 
combined with other antishivering interventions. The main disadvantage of buspirone is 
that it needs to be administered enterally, no IV formulation is available. Bioavailability in 
the critically ill may not be reliable.10 
Meperidine is an opioid analgesic. Meperidine is probably the single most useful 
antishivering drug, but has significant adverse events. Meperidine acts on both mu and 
kappa receptors, is considered the most effective antishivering agent among the opioids. 
The mechanism behind meperidine’s antishivering action is not clearly known. It is thought 
that activation of [kappa]-opioid receptors, anticholinergic action, and N-methyl-d-aspartate 
antagonism all play a role. In studies, plasma concentrations near 1.3 µg/mL have been 
required to induce moderate hypothermia with meperidine alone, which could increase the 
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risk of side effects. Meperidine is effective for postoperative shivering and, it inhibits 
shivering twice as much as vasoconstriction. 
Meperidine has major side effects; the more significant of them is lowering of seizure 
threshold. Other reported adverse events include arrhythmias, hyperreflexia, and 
myoclonus. The metabolite Normeperidine accumulates in patients with renal failure and 
could potentiate these adverse events.  
Fentanyl, morphine are pure mu opioid receptor agonists, and have had mixed results in 
studies. High doses may be needed to achieve this effect, and this may potentiate side 
effects11. 
The alpha2-receptor agonists are another important class of drugs used as pharmacologic 
measures to control shivering. Bradycardia and hypotension are the main adverse events 
with this class of drugs. Important to remember, they may also exacerbate the bradycardia 
induced by hypothermia. 
Clonidine decreases the vasoconstriction and shivering thresholds. Prophylactic use of 
clonidine lowered the threshold of vasoconstriction in healthy volunteers. 12, 13 In a trial 
comparing clonidine and meperidine, the average onset of action for meperidine and 
clonidine were 2.7 and 3.1 minutes, respectively. At least from these data, clonidine appears 
to be as effective as meperidine for postanesthetic shivering14 
Dexmedetomidine is another agent that has been shown to decrease postanesthetic 
shivering when compared to both placebo and Meperidine. In studies with 
dexmedetomidine in healthy volunteers, it showed a decrease in the vasoconstriction and 
shivering thresholds by similar amounts.15 
A small study looked at healthy volunteers and found that Meperidine and 
Dexmedetomidine were synergistic as well. 16, 17 
Magnesium is another anti shivering agent. It is thought to act as an antagonist of the 
NMDA receptors. In addition, hypothermia causes hypomagnesaemia commonly, and 
magnesium replacement is often required. Results on magnesium as a neuroprotectant have 
been variable. In a study of healthy volunteers, despite reducing the shivering threshold, the 
authors concluded that it was not clinically significant in counteracting the shivering effect 
of therapeutic hypothermia. 18 In another study, magnesium shortened the time to achieve 
target temperature and improved patient comfort. 
In this small study, 22 volunteers were randomly assigned to one of four therapies: 
meperidine monotherapy; meperidine plus buspirone; meperidine plus ondansetron; or 
meperidine, ondansetron, and magnesium sulfate. In this study, Magnesium was shown to 
decrease time to target temperature and increase patient comfort. Although the presence of 
shivering was recorded in this investigation, these data were not reported. 19 
Dantrolene is another agent that has been used for malignant hyperthermia. It acts on the 
skeletal muscle and interferes with the release of calcium from the sarcoplasmic reticulum, 
and inhibits the excitation-contraction coupling of skeletal muscles. It is a good adjunctive 
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antishivering agent. In a study with healthy volunteers, dantrolene decreased the gain of 
shivering. Dantrolene had no effect on the vasoconstriction threshold. Hepatitis is a 
complication of dantrolene, especially in people older than 35 years. The reaction can be 
dose dependent or idiosyncratic.20 
Propofol has been widely studied in Shivering control. It has been compared to Thiopental 
and isoflurane. Patients on propofol experienced less shivering compared to thiopental 
alone or thiopental plus isoflurane. Like other drugs, during hypothermia, the plasma 
concentration of propofol is increased by 30% due to reduced clearance. Clinicians should 
also be aware of propofol infusion syndrome.21 22 Propofol infusion syndrome is a rare 
complication of propofol infusion. Risk factors include administration of high doses (greater 
than 3-5 mg/kg per) and prolonged use, more than 48 hours, patients on catecholamines for 
vasopressor support, steroids. Additional proposed risk factors include a young age, critical 
illness, high fat and low carbohydrate intake, inborn errors of mitochondrial fatty acid 
oxidation. Patients present with cardiac dysrhythmias, metabolic acidosis, rhabdomyolysis, 
and renal failure. It can be associated with a high mortality. 
There is limited data on the use of other agents such as Ketamine, methylphenidate and 
doxapram as anti shivering agents in hypothermia. 
Drug metabolism 
By redistributing blood flow away from muscle, skin, and fat, hypothermia alters drug 
pharmacokinetics. Drugs with a large volume of distribution, in the setting of hypothermia 
distribute to reduced volume and thereby produce higher plasma concentrations. Due to 
reduced blood flow, these drugs may initially be sequestered in tissue, but subsequently 
with rewarming and vasodilation, these drugs now redistribute from tissues, leading to high 
plasma concentrations, thereby increasing the risk of toxicity.23 
Cardiovascular manifestations 
Cardiac output decreases, but this is offset by the decreased metabolic rate 
Common electrocardiographic findings during hypothermia include prolonged P-R and Q-T 
intervals and widening of the QRS complex as well as altered T waves and appearance of 
the J wave. (Osborne). These usually do not require interventions. 
Arrhythmias: Initially, hypothermia causes tachycardia, and then bradycardia ensues. The 
arrhythmias depend on the severity of hypothermia, more severe commonly occur at 
temperatures of < 28C. The bradycardia may be severe enough to warrant discontinuing 
hypothermia. This is compounded by the fact that the anti arrhythmics become less 
effective, and so does electrical defibrillation. Attempts at electrical defibrillation can initiate 
malignant arrhythmias.  
In the setting of a cardiac arrest, the myocardium in a deeply hypothermic patient is easily 
susceptible to manipulations such as CPR, defibrillation, and can predispose to arrhythmias. 
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While mild hypothermia can be protective by stabilizing membranes, severe hypothermia 
increases risk of malignant arrhythmias. 
Limited data exist on the efficacy of various antiarrhythmics. Bretylium, the most commonly 
studied agent, has been recommended as the drug of choice during moderate-to-severe 
hypothermia  
Observational data from humans and experimental animal models have looked at 
Bretylium. Bretylium is a parenteral Class III antiarrhythmic agent. However, Bretylium is 
no longer available in the US secondary to lack of availability of raw materials needed to 
produce the drug, as well as declining usage in clinical practice. Amiodarone has been 
studied in an animal model. Stoner et al looked at thirty anesthetized dogs and induced 
hypothermic VF. They compared defibrillation rates after drug therapy with amiodarone, 
bretylium, and placebo. In this study, neither amiodarone nor bretylium was significantly 
better than placebo in improving the resuscitation rate.24, 25.The benefits of amiodarone 
during hypothermia have not been clearly established in humans. In the Bernard study 
looking at hypothermia after cardiac arrest, Lidocaine was administered for 24 hrs. 
Clinically significant cardiac arrhythmias occurred with less frequency in the Australian 
study compared to the European study, where no lidocaine was employed. 6 
Coronary blood flow has been shown to decrease during mild hypothermia in patients with 
coronary artery disease. Evidence from animal studies has shown a 10% reduction in 
myocardial infarct size for every 1°C decrease in body temperature. 26 
Dixon et al looked at a randomized study of 42 patients with acute myocardial infarction 
and where cooling was maintained for 3 hours after reperfusion (core temperature target 33 
degrees C.)There were no significant adverse hemodynamic events with cooling; however, 
the median infarct size was not significantly smaller in those that were cooled compared 
with the control group27 
Other clinical studies of therapeutic hypothermia in patients with acute myocardial 
infarction who are undergoing primary PCI have not shown any beneficial effects.  
Despite these data, hypothermia can potentially cause hypotension and myocardial 
dysfunction. It induces a cold diuresis and induces hypovolemia. This is through increased 
venous return, stimulation of atrial natriuretic peptide, decreased anti diuretic hormone 
levels, and renal tubular dysfunction. 
Patients with severe Traumatic brain injury may also receive mannitol for hyperosmolar 
therapy for raised intracranial pressures or may have diabetes insipidus, which can further 
contribute to hypovolemia.4 
Infection 
Infectious complications occur frequently in ICU patients, especially after cardiac arrest. The 
increasing use of therapeutic hypothermia has raised awareness about increased infectious 
complications. In a retrospective review of a single institution cohort, Mongardon et al 
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found that pneumonia as the most common source, and Staphylococcus aureus was the 
main causative agent. Duration of hypothermia was associated with increased infection 
rates. ICU survival and neurologic outcome were not affected. 28A numbers of studies, 
especially in patients with stroke or TBI, have reported higher risks of pneumonia when 
therapeutic hypothermia is used over longer periods of time (48–72 h) However, other 
studies using hypothermia for prolonged periods in patients with TBI reported no increase 
in infection rates. 
Evidence from clinical and in vitro studies shows that hypothermia can impair immune 
function. Hypothermia inhibits the release of various pro-inflammatory cytokines, inhibit 
neutrophil and macrophage function.  Kimura and colleagues found that the peak release of 
interleukin-6, interleukin-1, and other proinflammatory cytokines was significantly delayed 
at 33 °C compared with 37 °C 29, 30 Hypothermia reduces gastrointestinal motility, and 
cardiac dysfunction in post arrest patients, therefore, it may increase risk of mucosal 
ischemia and breakdown. This may cause bacterial translocation. The insulin resistance and 
hyperglycemia associated with hypothermia may further predispose the patient to infection. 
The normal host responses to infection like leukocytosis may not be noted in hypothermic 
patients, so careful surveillance is needed. The threshold to initiate antibiotic treatment 
should be low. Fever in these patients should be treated aggressively to prevent further 
neurologic injury. 
Many institutions perform blood cultures and sputum cultures at the time of initiation of 
hypothermia, and periodic surveillance cultures to detect early bacteremia. In patients 
developing infections after hypothermia treatment, fever should be treated aggressively, to 
mitigate new or additional neurological injuries  
Seizures 
In a retrospective observational study involving neonates, moderate cooling decreased 
seizures recorded by EEG.31 Seizures after cardiac arrest and TBI are common; the detection 
of seizures is an important aspect of a neurointensivist in the care of therapeutic 
hypothermia patients.  Many of these patients are under neuromuscular blockade, and 
convulsive movements are absent. The incidence of seizures after cardiac arrest is around 
24%, with some studies showing a higher incidence than others. Continuous EEG 
monitoring should be used when available over intermittent EEG, because seizures could be 
no convulsive as well as convulsive in these patients. The disadvantage of continuous EEG 
is that is not always available, is expensive, labor intensive, and subject to misinterpretation. 
No clear guidelines exist to guide therapy of EEG findings like PLEDS. 
Intravenous benzodiazepines are used the initial medical treatment of status epilepticus. If 
the patient fails first line therapy and is considered to be in refractory status epilepticus, 
there is no firm data to guide subsequent management. The VA cooperative study showed 
that early control with a first line agent is important, because, if the first line agent fails, the 
success of subsequent second and third line agents is marginal. In the VA cooperative trial, 
the treatment success rate with the first drug was 55% in the overt status group and 15% in 
the subtle status group.32, 33   
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Many experts recommend continuous intravenous antiepileptic drugs at this stage. 
Midazolam is the safest anesthetic agent in treating SE. Doses as high as 3 to 5 mg/kg/h may 
be necessary to maintain seizure suppression in the most refractory cases. Tachyphylaxis is 
often encountered when prolonged infusions are used. The other agents used to treat SE are 
propofol, and barbiturates (Thiopental or pentobarbital). Barbiturates produce hypotension, 
and myocardial depression, this may pose further challenges in the post cardiac arrest 
setting. Other side effects include ileus, hepatotoxicity, increased susceptibility to infections 
and very prolonged sedation. Propofol can be associated with propofol infusion syndrome 
as discussed earlier. Valproic acid, levetiracetam, are emerging as alternative agents. 
Fosphenytoin is an antiepileptic that is often added in these patients. Fosphenytoin is a 
prodrug of phenytoin and its preparation does not include propylene glycol. It can be 
administered faster than IV phenytoin, and has less adverse cardiac events with IV infusion 
compared to phenytoin. It is much less likely to produce local tissue reactions, and it can be 
infused faster than phenytoin.34 As with status epilepticus from other causes, it is not clear 
whether burst suppression on EEG is superior to seizure suppression. No data on seizure 
prophylaxis after hypoxic ischemic encephalopathy are available 
9. Coagulation 
Bleeding diatheses occur in the setting of mild therapeutic hypothermia. For every 1 °C 
decrease in temperature, coagulation-factor function is decreased by 10%. Watts et al 
showed that in trauma patients, enzyme activity alteration, platelet dysfunction and changes 
in fibrin pathways occur. Clinically significant bleeding is rarely a significant problem, even 
in traumatic brain injury patients. Schefold et al. in a prospective observational study of 31 
patients with AMI and mild induced hypothermia and primary PCI found no excessive 
bleeding  risk with cooling/PCI.35,36  
Values of standard coagulation tests such as prothrombin time and partial thromboplastin 
times are usually normal, because these tests are usually performed at 37°C in the lab. Tests 
will be prolonged only if they are performed at the patient’s actual core temperature 
10. Pressure ulcers 
Skin integrity should be assessed carefully and frequently. The surface cooling, 
vasoconstrictive response to cooling can increase skin breakdown in hypothermic patients.6 
11. Gastrointestinal dysfunction 
Hypothermia patients have GI dysmotility, ileus. Caution needs to be exercised with 
promotility agents like Erythromycin, metoclopramide, neostigmine, as they can induce 
arrhythmias. Increased serum amylase levels are common, but patients rarely have 
significant pancreatitis. Enteral nutrition can help decrease risk of bacterial translocation. 
Gaussorgues P, et al. Bacteremia following cardiac arrest and cardiopulmonary 
resuscitation. Intensive Care Med 1988; 14(5):575-7. 
 
Therapeutic Hypothermia: Adverse Events, Recognition, Prevention and Treatment Strategies 17 
12. Hypovolemia, fluid balance and electrolytes, glycemia 
A common problem is severe electrolyte disorders hypokalemia, hypomagnesemia, 
hypophosphatemia during induction of cooling. These may cause further arrhythmias in 
post-arrest patients. Hypothermia decreases insulin sensitivity and insulin secretion, which 
often leads to hyperglycemia. Tight control of glucose levels may decrease morbidity and 
mortality in ICU patients, but the exact levels at which glycemia needs to be maintained is 
controversial. During rewarming, glucose levels tend to drop, and therefore, insulin may 
need to be decreased or discontinued. Likewise, hyperkalemia and hypermagnesemia are 
common during rewarming, and cardiac arrests have occurred when the clinician s unaware 
of this phenomenon. Hypothermia also induces a metabolic acidosis by increased synthesis 
of glycerol, free fatty acids, ketones and lactate. These changes are normal metabolic 
consequences of hypothermia and should not be attributed to complications such as bowel 
ischemia.4 
Hypotension can occur  through hypovolemia, the cold diuresis, that occurs in hypothermia, 
and the use of agents like mannitol in TBI or diuretics in the setting of cardiomyopathies can 
further  exacerbate this. If this is unrecognized, the problem is worse in the rewarming 
phase when vasodilatation often occurs, and profound shock ensues. Cueni-Villoz N, et al.  
13. Summary 
In conclusion, hypothermia is becoming increasingly used across many intensive care units, 
and the applications could expand well beyond the current indications. It is important to use 
safe, effective cooling methods, recognize, prevent and treat various adverse events that 
could occur, so we can improve the survival of these patients. 
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